GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Resonance Health Ltd (ASX:RHT) » Definitions » YoY EPS Growth

Resonance Health (ASX:RHT) YoY EPS Growth : 300.00% (As of Jun. 2024)


View and export this data going back to 1987. Start your Free Trial

What is Resonance Health YoY EPS Growth?

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months. Resonance Health's YoY EPS Growth for the quarter that ended in Jun. 2024 was 300.00%.

Resonance Health's Earnings per Share (Diluted) for the six months ended in Jun. 2024 was A$0.00.

Resonance Health YoY EPS Growth Historical Data

The historical data trend for Resonance Health's YoY EPS Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Resonance Health YoY EPS Growth Chart

Resonance Health Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
YoY EPS Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only -166.67 150.00 -400.00 33.33 100.00

Resonance Health Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
YoY EPS Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 50.00 - 300.00

Resonance Health YoY EPS Growth Calculation

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months.

Resonance Health's YoY EPS Growth for the fiscal year that ended in Jun. 2024 is calculated as:

YoY EPS Growth (A: Jun. 2024 )
=(Earnings per Share (Diluted) (A: Jun. 2024 )-Earnings per Share (Diluted) (A: Jun. 2023 ))/ | Earnings per Share (Diluted) (A: Jun. 2023 ) |
=(0--0.002)/ | -0.002 |
=100.00 %

Resonance Health's YoY EPS Growth for the quarter that ended in Jun. 2024 is calculated as:

YoY EPS Growth (Q: Jun. 2024 )
=(Earnings per Share (Diluted) (Q: Jun. 2024 )-Earnings per Share (Diluted) (Q: Jun. 2023 )) / | Earnings per Share (Diluted) (Q: Jun. 2023 )) |
=(0.002--0.001)/ | -0.001 |
=300.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Resonance Health YoY EPS Growth Related Terms

Thank you for viewing the detailed overview of Resonance Health's YoY EPS Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Resonance Health Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Resonance Health Ltd (ASX:RHT) » Definitions » YoY EPS Growth
Comparable Companies
ASX:BB1 ASX:HIQ ASX:IME ASX:EMD ASX:VFX ASX:TRI ASX:GLH ASX:PHX ASX:ICR ASX:OPL GEHC VEEV ASX:PME SOLV DOCS HQY WAY TSE:2413 TEM NSE:IKS
Traded in Other Exchanges
N/A
Address
141-143 Burswood Road, Level 1, Burswood, Perth, WA, AUS, 6100
Website
https://www.resonancehealth.com
Resonance Health Ltd is a healthcare company specializing in the development and commercialization of technologies and services for the quantitative analysis of radiological images in a regulated and quality-controlled environment. Its product includes FerriScan, a non-invasive liver diagnostic technology used for the measurement of iron in the liver, Cardiac T2, and HepaFat-Scan. It also has several AI-assisted SaMDs including FerriSmart, HepaFat-AI, and LiverSmart. The company's business segments are; Services which derives key revenue, Research and development, Corporate, Clinical Research Organization (CRO), and TrialsWest. Geographically, it generates maximum revenue from the Asia Pacific and the rest from North America, and Europe, Middle East and Africa (EMEA) regions.

Resonance Health Headlines

No Headlines